Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

qXR-LN is an FDA-cleared solution to assist physicians with early nodule detection. Studies have shown that AI is highly ...

In the ILIAS ANOCA trial, using CFT to guide treatment according to ANOCA endotype led to larger QoL gains over 6 months.

Pulmonary function tests (PFTs) are frequently normal in patients with sarcoidosis, despite evidence of abnormal chest radiography.

Skolnik said, “For example, pulmonary function tests like spirometry are very helpful in gaining insight as to whether ...

Artificial intelligence (AI) is a branch of computer science developed in the 1950s to imitate the human ability for solving ...

A recent study found that pulmonary rehabilitation significantly improved physical capacity, respiratory function, HRQOL, ...

fewer than half of patients with abnormal lung function demonstrate a restrictive phenotype on pulmonary function testing.12 This raises concerns that trials relying solely on FVC as the primary ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

For initial treatment of symptomatic pulmonary sarcoidosis, methotrexate appeared to work as well as prednisone over 24 weeks ...